Results 111 to 120 of about 28,620 (235)

Association between CYP2C19 gene polymorphisms and Helicobacter pylori infection in Hainan region

BMC Infectious Diseases
Objective This study was to investigate CYP2C19 gene and their association with H. pylori infection in the region of Hainan. Methods We conducted CYP2C19 genotype analysis in Hainan.
Shimei Huang, Daya Zhang, Da Li, Chen Chen, Fan Zeng, Shiju Chen, Runxiang Chen, Xiaodong Zhang, Feihu Bai   +8 more
doaj   +1 more source

Exploring the Potential Role of CYP2C19 Genetic Variability in Cenobamate Treatment

Applied Sciences
Background: Cenobamate is a novel antiseizure medication with potential interactions involving cytochrome P450 enzymes, including CYP2C19. Genetic variability in CYP2C19 may influence drug metabolism and tolerability, although its clinical relevance in ...
Giovanni Falcicchio, Valeria Delmonte, Teresa Francavilla, Alessandro Introna, Maria Addolorata Mariggiò, Mariella Pafundi, Mirko Perrone, Angela Vinella, Emilio Russo   +8 more
doaj   +1 more source

Escitalopram Personalized Dosing: A Population Pharmacokinetics Repository Method

Drug Design, Development and Therapy, 2023
Xin Liu,1– 3 Gehang Ju,1– 3 Wenyu Yang,4 Lulu Chen,3,5,6 Nuo Xu,4 Qingfeng He,4 Xiao Zhu,4,* Dongsheng Ouyang1– 3,5,* 1Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, People’s Republic of China ...
Liu X, Ju G, Yang W, Chen L, Xu N, He Q, Zhu X, Ouyang D   +7 more
doaj  

Characterization of Lysosomal Hydrolases and Transporters and Their Age‐Dependent Variability: Relevance to Drug Metabolism and Transport of Small Molecule and Biologic Drugs

Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1338-1347, November 2026.
Lysosomes play a key role in the accumulation, catabolism, and transport of endogenous and exogenous metabolites and proteins and are involved in drug metabolism and prodrug activation. However, the protein abundance and interindividual variability of lysosomal drug‐metabolizing enzymes and transporters (DMETs) remain underexplored.
Darshak Gadara, Dilip Kumar Singh, Sandhya Subash, Guihua Yue, Deepak Ahire, Chris Bohl, Maciej Czerwinski, Stephanie Helmstetter, Scott Heyward, Robert S. Jones, Cyrus Khojasteh, Ryota Kikuchi, Priyanka Kulkarni, Bin Ma, Bernard Murray, Chris Seib, Bill Smith, David M. Stresser, Mitchell E. Taub, Ting Wang, Bhagwat Prasad   +20 more
wiley   +1 more source

Integrated assessment of rifampicin‐mediated induction of transporters and drug‐metabolizing enzymes in a long‐term human liver tissue chip system

Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1368-1378, November 2026.
Rifampicin is a prototypical clinical inducer used in drug–drug interaction (DDI) studies. However, the clinical relevance and predictability of rifampicin‐mediated hepatic transporter induction remain poorly defined. Conventional hepatocyte culture models fail to capture clinically relevant regulation of transporters and drug‐metabolizing enzymes ...
Mattie E. Hartauer, Raeanne M. Lanphier, Shivam Ohri, Jessica Snyder, Jacqueline B. Tiley, John K. Fallon, Henry Ho, Murat Cirit, Shiny Amala Priya Rajan, Kim L. R. Brouwer   +9 more
wiley   +1 more source

Do CYP2C19 and ABCB1 gene polymorphisms and low CYP3A4 isoenzyme activity have an impact on stent implantation complications in acute coronary syndrome patients?

, 2017
Eric Rytkin,1 Karin B Mirzaev,1 Elena A Grishina,1 Valeriy V Smirnov,2 Kristina A Ryzhikova,1 Zhannet A Sozaeva,1 Michael Iu Giliarov,2 Denis A Andreev,2 Dmitriy A Sychev1 1Russian Medical Academy of Continuous Professional Education, 2I.M.
Rytkin E, Smirnov VV, Ryzhikova KA, Sychev DA, Sozaeva ZA, Grishina EA, Andreev DA, Mirzaev KB, Giliarov MI   +8 more
core  

Advances in New Approach Methodologies at FDA's Division of Applied Regulatory Science

Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1250-1254, November 2026.
New Approach Methodologies (NAMs) represent a paradigm shift in drug development and regulatory science, offering human‐relevant alternatives to traditional preclinical models. This mini‐review highlights recent advances in NAM development, validation, and regulatory application from FDA's Division of Applied Regulatory Science (DARS).
Ksenia Blinova, Kimberly Chiu, Anik Chaturbedi, Jahan Cooper, Tromondae K. Feaster, Paula L. Hyland, Lidiya Stavitskaya, Wendy W. Wu, Jeffry Florian, Rodney Rouse   +9 more
wiley   +1 more source

Novel Carbazole–Acylthiourea Derivatives: Synthesis, Antimicrobial, Antioxidant, Hemocompatibility, Cytotoxicity, and ADME‐Tox Profiling

ChemistryOpen, Volume 15, Issue 11, November 2026.
We synthesized four novel carprofen‐derived carbazole–acylthiourea propanamides with selective antimicrobial activity against Staphylococcus aureus, Enterococcus faecalis, and Candida albicans. Compound 1a provides combined antioxidant and antihemolytic protection.
Carmen Limban, Ioana Cristina Marinaş, Mariana Carmen Chifiriuc, Miron Teodor Căproiu, Florea Dumitraşcu, Erzsébet‐Eleonóra Kapronczai, Irina Zarafu, Diana Camelia Nuţă, Petre Ioniţă, Speranţa Avram, Cătălina Mareş, Andra Maria Păun, Bogdan Mihai Cristea, Carmellina Daniela Bădiceanu, Ilinca Margareta Vlad, Maria Coandă, Delia Laura Popescu, Coralia Bleotu   +17 more
wiley   +1 more source

Machine Learning–Augmented Precision Dosing: Integrating Pharmacokinetic Modeling With Clinical Decision Support

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 11, November 2026.
ABSTRACT Inter‐individual variability in drug exposure can lead to ineffective therapy or toxicity, particularly in vulnerable patients. Routine model‐informed precision dosing (MIPD) relies mainly on population pharmacokinetic (PopPK) models, Bayesian forecasting, and therapeutic drug monitoring (TDM).
Yunmeng Pang, Bingqi Zhang, Zhiqiu He, Yuliu Li, Jiaxin Yu, Wei Zuo   +5 more
wiley   +1 more source

Identifying Dose‐Relevant Covariates With SCOUT: A Case Study of Lorlatinib

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 11, November 2026.
ABSTRACT Molecularly targeted therapeutics, such as lorlatinib, are typically initiated at fixed starting doses with subsequent tolerability‐guided modifications, although substantial interindividual variability in pharmacokinetics and drug exposure may influence both efficacy and safety outcomes.
Yasuhisa Ideno
wiley   +1 more source